A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine | Zendy

Nittaya Phanuphak | Zendy; Jintanat Ananworanich | Zendy; Nipat Teeratakulpisarn | Zendy; Tanate Jadwattanakul | Zendy; Stephen J. Kerr | Zendy; Nitiya Chomchey | Zendy; Piranun Hongchookiat | Zendy; Pornpen Mathajittiphun | Zendy; Suteeraporn Pinyakorn | Zendy; Patcharawee Rungrojrat | Zendy; Pairoa Praihirunyakit | Zendy; Mariana Gerschenson | Zendy; Praphan Phanuphak | Zendy; Victor Valcour | Zendy; Jérôme H. Kim | Zendy; Cecilia M. Shikuma | Zendy

Open Access

A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine

Author(s) -

Nittaya Phanuphak,

Jintanat Ananworanich,

Nipat Teeratakulpisarn,

Tanate Jadwattanakul,

Stephen J. Kerr,

Nitiya Chomchey,

Piranun Hongchookiat,

Pornpen Mathajittiphun,

Suteeraporn Pinyakorn,

Patcharawee Rungrojrat,

Pairoa Praihirunyakit,

Mariana Gerschenson,

Praphan Phanuphak,

Victor Valcour,

Jérôme H. Kim,

Cecilia M. Shikuma

Publication year - 2012

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2497

Subject(s) - zidovudine , stavudine , lamivudine , nevirapine , medicine , gastroenterology , emtricitabine , viral load , pharmacology , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , hepatitis b virus , virus , viral disease

Due to superior long-term toxicity profiles, zidovudine (AZT) and tenofovir disoproxil fumarate (TDF) are preferred over stavudine (d4T) for first-line antiretroviral regimens. However, short-term d4T use could be beneficial in avoiding AZT-induced anaemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research